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1. Introduction 
Combined radiotherapy and chemotherapy with the alkylating agent, temozolomide plus an 
additional six cycles of temozolomide has been the mainstay of treatment for patients 
diagnosed with glioblastoma for the past 6 years. Clinically, high variability in the response 
to this treatment is typically observed, with some patients enjoying progression free survival 
for longer than others. However, tumour relapse is inevitable in the majority of patients. 
Local tumour recurrence, occurring within 2-3cm of the original resection cavity (the area 
exposed to radiation treatment) is most frequently observed. Relapsed glioblastomas are 
typically unmanageable with median survival after recurrence of only a few months (Brandes et al. 
2001). Numerous chemotherapeutic agents have been trialled in patients with recurrent 
glioblastomas and include enzastaurin (Wick et al. 2010), immunotherapeutic targeting of 
EGFRvIII (Sampson et al. 2011), cilengitide (trial ongoing) (Reardon et al. 2011), NovoTTF-
100A (trial ongoing), gefitinib (Uhm et al. 2010), imatinib (Dresemann et al. 2010), 
bevacizumab plus irinotecan (Vredenburgh et al. 2007). Only bevacizumab has shown 
promise for the treatment of recurrent glioblastoma, although the benefits of such a drug are 
still debatable. The Food and Drug Administration (FDA) in the USA approved 
bevacizumab for GBM under its accelerated approval process. However in Europe, the 
Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion. 
As new therapeutic regimes are developed, it is paramount that we develop a strategy for 
identifying the patients that will show a positive response to treatment. The recognition and 
validation of biomarkers of clinical response is important for several reasons: to avoid 
unnecessary toxicity in patients that fail to respond to the particular treatment; to reduce the 
colossal cost to healthcare which is typically associated with targeted therapy and most 
importantly, to better understand drug resistance. This improved knowledge could lead to 
new strategies to overcome the initial resistance and identify synergistic drug combinations.  
1.1 Prognostic and predictive biomarkers 
Hopes for progressing curative treatment programs for cancer patients centre on the 
development and successful implementation of personalised medicine. Personalised 
medicine hinges on biomarkers which are highly sensitive and highly specific in revealling 
information that is relevant for diagnosis, prognosis and therapy. The most sought after 
biomarkers are the ones that can identify which patients are at high risk of tumour relapse 
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and developing cytotoxicity to specific chemotherapeutic agents. The use of biomarkers to 
identify patients who don’t respond to treatment early could confer enormous benefits for 
patients diagnosed with glioblastoma, especially considering the short survival time. Many 
biomarkers have shown excellent utility in survival prognostication but not necessarily at 
the level of influencing an oncologist’s decision to administer a specific drug or alter the 
treatment schedule (Figure 1). In addition, another challenge in oncology is the translation 
of prospective biomarkers from the lab into validated diagnostic tests.  
 
BIOMARKER
PROGNOSTIC PREDICTIVE
capacity to estimate survival outcome in 
patients, independent of treatment
identify groups of patients who are most 
likely to respond to a given treatment
The key difference between a prognostic and a predictive biomarker is that the predictive 
biomarker should instigate a change in the treatment provided to the patient 
 
Fig. 1. Schematic overview of the key difference between biomarkers with prognostic and 
predictive qualities. Prognostic markers are more common in glioblastoma. 
Most biomarkers often have both prognostic and predictive value. There is no strict rule 
when it comes to what constitutes a biomarker. A marker can consist of genomic and 
proteomic patterns, single genes or proteins, chromosomal abnormalities, epigenetic 
signatures, aberrant microRNA as well as imaging changes observed on a MRI or PET scan. 
A prognostic marker has the capacity to estimate survival outcome in patients, 
independent of treatment. The genetic profiling of large tumour cohorts with 
comprehensive clinical and survival data have promoted the discovery of novel molecular 
biomarkers associated with survival, in addition to traditional clinical and morphological 
features. Examples of biomarkers with prognostic significance include amplification of 
Epithelial Growth Factor Receptor (EGFR) (Shinojima et al. 2003; Layfield et al. 2006; Kaloshi 
et al. 2007; Gan et al. 2009; Inda et al. 2010), over-expression of chitinase-3-like-1 (CH3L1 or 
YKL-40) (Hormigo et al. 2006; Pelloski et al. 2007), osteopontin (Sreekanthreddy et al. 2010), 
loss of phosphatase and tensin homolog (PTEN) (Hill et al. 2003; Parsa et al. 2007) and 
mutations in the tumour suppressor protein, p53 (Shiraishi et al. 2002; Ruano et al. 2009). 
Prognostic biomarkers have great utility in the clinic. Not only do these markers present as 
potential therapeutic targets but they can be used to pool groups of glioma with similar 
genetic profile. This enrichment of the test population leads to increased homogeneity and a 
much more uniform response to treatment (Figure 2).  
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Fig. 2. Molecular diagnostics allows for the identification of GBM subgroups with similar 
genetic profile. This enrichment allows for a more uniform tumour response. 
Much more difficult to identify are biomarkers with predictive power in the context of a 
specific therapy. Predictive biomarkers are markers which can be used to identify groups of 
patients who are most likely to respond to a given treatment. The key difference between a 
prognostic and a predictive biomarker is that the predictive biomarker should instigate a 
change in the treatment provided to the patient (Figure 1). Estrogen Receptor (ER) status in 
patients with breast cancer strongly predicts treatment response to tamoxifen (Kurokawa et 
al. 2000; Hu&Mokbel 2001). Additionally, patients with variant forms of the gene CYP2D6 
(also called simply 2D6) may not receive full benefit from tamoxifen because of the slow 
metabolism of the tamoxifen prodrug into its active metabolite 4-hydroxytamoxifen (Goetz 
2010; Stingl et al. 2010; de Souza&Olopade 2011). Approximately 60% of malignant 
melanomas harbour the BRAF mutation. Although patients with the damaged BRAF are 
non-responsive to the KRAS/BRAF inhibitor, sorafenib, response to the second-generation 
drug called PLX4720 is favourable (Whittaker et al. 2010). Improved outcomes have also 
been reported in patients with non-small cell lung cancer (NSCLC) harbouring EGFR 
mutations treated with the tyrosine kinase inhibitors (TKI) erlotinib and gefitinib (Kim et al. 
2008; Paz-Ares et al. 2010). 
In a highly heterogeneous tumour such as glioblastoma, the search for predictive markers to treatment 
for use in clinical trials and in every day clinic has been disappointing. 
1.2 Molecular subtypes of glioblastoma 
Most centres around the world use the World Health Organisation (WHO) grading of 
tumours of the central nervous system (Fuller&Scheithauer 2007). Glioma grade is defined 
by the presence or absence of histopathological features, namely: nuclear pleomorphism, 
mitoses, proliferative index and necrosis and/or microvascular proliferation. A significant 
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limitation to this histopathology-based analysis is its inability to detect functional 
differences occurring on the subcellular level. This is evidenced by the high variability 
observed in the clinical outcomes in patients with the same diagnosis and differences in 
response to therapy. To advance survival times and clinical treatment of these patients with 
an, on average, dismal prognosis molecular markers with capacity to take into consideration 
the high molecular heterogeneity are needed in the clinic. 
The wide spectrum of molecular difference in glioblastoma is evident from global 
expression studies, in particular, the molecular cataloguing project: The Cancer Genome 
Atlas (TCGA) (2008). Surveying the mutational environment of glioblastoma revealed that 
aberrations occur most commonly in genes whose protein products regulate the core cell 
growth signalling pathways that are already known to be important such as EGFR, PTEN, 
p53 and CDKN2A. What this survey did reveal was the extent of genomic complexity. Each 
tumour harbours different mutations. In addition, we are beginning to appreciate that the 
core pathways of cancer are not linear, rather complex and interacting. Given this 
complexity, it is very unlikely that a single genetic change will predict treatment response. 
Gene expression profiling has provided an opportunity to further define prognostic and 
predictive factors (Settle&Sulman 2011). Gene signatures have successfully categorised 
glioblastomas that histologically appear indistinguishable, into molecular subgroups which 
often have very different clinical outcomes (Colman et al. 2010; Verhaak et al. 2010). Based 
on survival associated genes, 76 high grade gliomas were classified into the broad 
genotology groups; proneural, mesenchymal and proliferative (Phillips et al. 2006). The use 
of larger and multiple datasets have refined these subtypes into two broad groups, 
proneural and mesenchymal angiogenic (Colman et al. 2010). Overexpression of a 
mesenchymal gene expression signature and loss of a proneural signature are associated 
with a poor prognosis group. By subtyping glioblastoma into mesenchymal and proneural 
subtypes, the sameness of patient populations is improved. In addition, the genes belonging 
to each group provides biologists hints for therapeutic targeting. For example, the 
mesenchymal subtype of glioblastoma is over-represented by genes involved in 
angiogenesis and invasion (Colman et al. 2010). This subgroup of patients is more 
responsive to bevacizumab. Mutation in the isocitrate dehydrogenase 1 (IDH1) gene is 
strongly associated with the proneural subtype of glioblastoma and a much better prognosis 
(Noushmehr et al. 2010). Increasing evidence suggests that proneural glioblastomas have a 
different histogenic origin which is further supported by the recent discovery of a glioma-
CpG island methylator phenotype (G-CIMP) (Noushmehr et al. 2010). Both IDH1mt and the 
G-CIMP have a higher incidence in secondary GBMs which arise from a prior, lower grade 
lesion. MGMT promoter methylation, G-CIMP and mutations in IDH1 are all prognostic. 
Although a correlation between proneural GBM subtypes and specific treatment has not 
been determined, it has been suggested by a few studies that chemotherapy agents such as 
temozolomide and others targeted at cell growth may not be as effective for this group as 
previously thought (Verhaak&Valk 2010). 
2. Prognostic biomarkers in glioma 
Molecular markers identified to hold prognostic significance in glioma include loss of 
heterozygosity of the chromosomal arms 1p and 19q (LOH 1p/19q), methylguanine 
methyltransferase (MGMT) promoter methylation, mutations in the isocitrate 
dehydrogenase 1 (IDH1) gene, mutations in TP53, loss of PTEN activity, amplification of 
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EGFR, presence of the EGFR delta variant (EGFRvIII) and overexpression of chitinase 3-like 
1 (YKL40). Gene profiling and cross validation in multiple independent datasets has 
resulted in the separation of glioblastoma into two major subgroupings: proneural and 
mesenchymal. The proneural tumours have a much better survival outlook and can be 
further characterised by the presence of a glioma CpG island methylation phenotype 
(gCIMP).  
Extensive reviews of EGFR, PTEN and TP53 are covered elsewhere. This discussion will 
focus on LOH 1p/19q, MGMT promoter methylation and mutations in IDH. 
2.1. Loss of heterozygosity 1p and 19q 
A hallmark of oligodendroglial tumours is the co-deletion of the chromosomal arms 1p and 
19q corresponding to an unbalanced translocation t(1;19) (q10;p10). This can be readily 
detected using Fluorescence In situ hybridisation (FISH) (Figure 3). LOH at 1p19q is 
observed in up to 69% of grade II and grade III (anaplastic) oligodendrogliomas and is far 
more common in ‘pure’ oligodendroglioma than astrocytoma and mixed oligoastrocytoma 
(Barbashina et al. 2005). LOH of 1p19q confers a clear survival advantage in anaplastic 
oligodendroglioma and mixed oligoastrocytoma however the survival advantage conferred 
for grade II lesions is less clear (Laigle-Donadey et al. 2005; Jenkins et al. 2006; Walker et al. 
2006) . Whether the co-deletion mediates a prognostic advantage or results in a heightened 
sensitivity to radiation and chemotherapy is unknown. In general, oligodendrogliomas with 
LOH at 1p19q represent a group of highly chemosensitive gliomas, especially to the 
combination of procarbazine, lomustine (CCNU), and vincristine (PCV).  
 
A B
 
 
Fig. 3. Representative photomicrographs of loss of 1p (A) and loss of 19q (B) chromosomal 
arms detected using FISH. Arrow indicates only one chromosome copy instead of the 
expected two. Photomicrographs were kindly donated by Dr Michael Buckland, Department 
of Neuropathology, University of Sydney. 
The standard treatment for anaplastic oligodendrogliomas consists of complete surgical 
removal where possible followed by radiation therapy and chemotherapy, typically with 
temozolomide because it is well tolerated. It is generally accepted that chemotherapy is of 
value in the treatment of patients with anaplastic oligodendrogliomas (Mokhtari et al. 2011). 
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Because of the potential toxicity to the CNS, many clinicians have suggested that 
radiotherapy treatment may be better reserved for progressive disease. Treatment with 
temozolomide is now favoured over PVC treatment because of its low toxicity. Studies 
treating anaplastic oligodendroglioma patients with temozolomide have also found that the 
presence of LOH at 1p/19q is a favourable predictive marker (Brandes et al. 2006; Mikkelsen 
et al. 2009; Ramirez et al. 2010). This could also be because the majority of 
oligodendrogliomas harbouring LOH at 1p/19q also show methylation in the promoter 
region of MGMT. Clinical studies have been designed to establish whether combining or 
adding chemotherapy to radiotherapy is of benefit to oligodendroglioma patients or 
whether these patients could benefit from upfront chemotherapy (without radiotherapy).  
Two large prospective trials have shown little benefit for adding adjuvant PVC before 
radiotherapy (Cairncross et al. 2006) or after radiotherapy (van den Bent et al. 2006). To 
address whether treatment of oligodendrogliomas with chemotherapy alone is feasible and 
safe, the NOA-04 Phase III trial compared radiotherapy versus chemotherapy with either 
PCV or temozolomide as initial therapy in 318 patients with anaplastic gliomas (WHO grade 
3) (randomly assigned 2:1:1 to receive radiotherapy (arm A) or chemotherapy with either 
PCV (arm B1) or temozolomide (arm B2)) (Wick et al. 2009). The clinical relevance of 1p/19q 
codeletion, O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation, and 
IDH1 mutations in codon 132 in these tumours were also measured and analysed. This 
important trial confirmed that there was no survival difference in administering initial 
radiotherapy or initial chemotherapy (Wick et al. 2009). One very important finding to 
emerge from the study was the presence of mutations in IDH1 provided the best prognostic 
model. An ongoing EORCT 26081 Phase III trial of radiotherapy, temozolomide and 
concomitant and adjuvant temozolomide in patients with anaplastic oligodendrogliomas 
with 1p/19q codeletions will further confirm what the optimal treatment for these tumours 
is (more information below). 
The gene products that are affected as a result of LOH remain under investigation and may 
include mediators of cytotoxic resistance or may represent an early oncogenic lesion still 
retaining sensitivity to genotoxic agents or insults. Microarray technology has been used to 
profile gene expression in oligodendrogliomas to look for putative tumour suppressor gene 
candidates and genes which could mediate the observed chemosensitivity using a variety of 
microarray platforms (Mukasa et al. 2002; Nutt et al. 2003; Mukasa et al. 2004; Tews et al. 
2006; Tews et al. 2007; Ducray et al. 2008). These studies have identified some interesting 
gene candidates located on the 1p and 19q chromosomal arms however none have gone on 
to be validated prospectively. Interestingly, these profiling experiments identified a 
proneural signature associated with 1p19q codeleted oligodendrogliomas and a better 
survival outcome (Phillips et al. 2006). In contrast, the mesenchymal signature is more 
commonly associated with glioblastoma (discussed in more detail below). Noteworthy is the 
absence of EGFR amplifications in the proneural group. Ducray and colleagues compared 
1p19q codeleted gliomas to EGFR-amplified gliomas and found that the proneural gene 
internexin (INA) which encodes neurofilament-interacting protein was significantly 
differentially expressed (Ducray et al. 2009). The prognostic significance of INA was further 
assessed and confirmed in the prospective, randomized EORTC 26951 trial of adjuvant PVC 
(Mokhtari et al. 2011). INA strongly correlated with 1p19q codeletion, mutated IDH1 and 
MGMT promoter methylation.  
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2.2 MGMT 
The O6-methylguanine-DNA methyltransferase gene, MGMT, located on chromosome 
10q26.1 encodes a DNA repair protein that restores mutagenic O6-alkylguanine to normal 
guanine within genomic DNA. O6-alkylguanines can pair erroneously with thymine during 
DNA replication, resulting in G:C>A:T transitions, as well as causing cross-links between 
adjacent strands of DNA, both of which can lead to neoplastic transformation (Gerson 2004). 
MGMT thus protects cells from the toxic and carcinogenic effects of alkylating agents and is 
absent in many types of human malignancy. Loss of MGMT protein expression is frequently 
associated with transcriptional silencing of the MGMT gene by methylation of its CpG 
island promoter in various neoplasia, (Esteller et al. 1999) as exemplified by 35-55% of 
gliomas (Silber et al. 1998; Esteller et al. 2000; Nakamura et al. 2001; Kamiryo et al. 2004; Paz 
et al. 2004; Brell et al. 2005; Hegi et al. 2005). However, several large studies of glioma have 
shown the correlation between immunohistochemical loss of MGMT and promoter 
methylation is not always correlative (Preusser et al. 2008; Cao et al. 2009; Hawkins et al. 
2009; Mellai et al. 2009). 
Alkylating drugs such as temozolomide are used in chemotherapy for the targeted cell 
death of rapidly-replicating neoplastic cells and MGMT expression is a key factor in 
conferring resistance to these agents. In 2005, a new treatment regime was developed and 
tested in a randomised, phase III clinical trial whereby the alkylating agent, temozolomide 
was combined with radiotherapy (RT) in concurrent treatment followed by an additional 6 
cycles of Temozolomide for newly diagnosed glioblastoma (Stupp et al. 2005). This was the 
first trial to achieve a clinically meaningful and statistically significant overall median 
survival benefit of 2.5 months when compared to radiotherapy alone. More compelling were 
the two-year survival rates with 26% of patients treated with concurrent treatment still alive 
after two years compared with just 10.4% for patients treated with radiotherapy alone. 
These survival benefits were still apparent after 5 years of follow-up (Stupp et al. 2009).  
The molecular basis for the differential response of glioblastoma patients to temozolomide 
has been recognized. Temozolomide is an oral alkylating chemotherapy which is 
spontaneously converted into its active metabolite and readily crosses the blood-brain 
barrier. The primary mode of action of temozolomide is to damage the DNA by introducing 
alkyl adducts. These cause genetic mutations as well as cross-links between DNA strands 
that inhibit DNA replication and thereby trigger cell death. Thus alkylating agents target 
rapidly replicating neoplastic cells. However, while temozolomide introduces alkyl adducts 
into DNA, MGMT reverses them. Thus tumour cells expressing MGMT are chemoresistant 
to this class of drugs (Pegg 1990). In a companion laboratory study to the phase III trial 
combining radiotherapy with temozolomide, Hegi et al. demonstrated a pronounced 
positive survival response in patients whose tumours had lost MGMT by promoter 
methylation. Strikingly, patients whose tumours were MGMT-methylated demonstrated 
extended overall and progression-free survival compared to those whose tumours were 
unmethylated, and therefore MGMT methylation was postulated to be a positive predictor 
of patient response to alkylating agents (Esteller et al. 2000; Hegi et al. 2005). Since these 
seminal reports in 2005, the standard of care for patients diagnosed with glioblastoma has 
comprised surgery with maximal feasible resection and radiotherapy with concurrent and 
adjuvant temozolomide. Yet widespread adoption of MGMT methylation as a marker of 
response to temozolomide in clinical practice has not transpired.  
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2.2.1 Routine testing for MGMT methylation 
While MGMT methylation could be routinely used as a prognostic/predictive marker in 
glioblastoma, there is so far no consensus on the method to be applied. Assessment of 
MGMT promoter methylation is difficult due to the complex nature of the techniques 
involved. To detect methylation, bisulfite treatment of the DNA is required, a process that 
may result in degradation of DNA and subsequent low success rates in PCR. This is further 
compounded by the fact that the most commonly available tissue for assessment is formalin 
fixed paraffin embedded (FFPE), and the DNA subsequently extracted from this tissue is 
usually fragmented, again making PCR more difficult.  
Promoter methylation analysis by qualitative methyl-specific polymerase chain reaction 
(MSP) or semi-quantitative methyl-specific polymerase chain reaction (SQ-MSP), especially 
from FPPE tissue is technically demanding. MSP is the more limited because the 
methylation status of only a few CpG sites (i.e., those interfering with the PCR primer 
binding) can be interrogated at once. The technique also has the drawback of providing only 
a qualitative indication of the methylation status of the sites. Karayan-Tapon (Karayan-
Tapon et al. 2010) evaluated MGMT promoter methylation using MSP, SQ-MSP and 
pyrosequencing. The best predictive value for overall survival was obtained by 
pyrosequencing. Pyrosequencing technology is a technique that generates a quantitative 
measure of methylation and automatically calculates and reports percent methylation for 
each CpG site in the studied sequence, thus allowing detection of partially methylated CpG 
sites. 
There are other methodologies for assessing the promoter methylation of MGMT. The 
testing needs to be resolved for MGMT to be used routinely in the clinic and perhaps a 
surrogate marker of MGMT such as another protein product readily visualised by 
immunohistochemistry or a polymorphism detected in blood may be the way forward.  
2.2.2 Strategies to overcome MGMT activity  
With the recognition that an unmethylated MGMT promoter is associated with a poorer 
response to temozolomide, strategies have evolved to circumvent the resistance that MGMT 
confers. Combination therapy with multiple chemotherapeutic drugs known to deplete 
MGMT (specifically procarbazine and temozolomide) has been successfully assessed in a 
Phase I trial (Newlands et al. 2003) but as yet has not been shown to confer a benefit in 
survival. O6 benzylguanine (O6BG), a substrate for MGMT, has also been used to decrease 
MGMT levels. However, systemic administration of O6BG has been associated with 
significant toxicity, thereby necessitating a reduction in chemotherapy dose (Quinn et al. 
2002; Quinn et al. 2005). A recent case report of local administration of O6BG, allowing the 
systemic effects to be avoided, shows some promise (Koch et al. 2007).  
Alteration of temozolomide dosing regimens from the usual method of 5 days of treatment 
every 28 days to more frequent, lower-dose treatment has been evaluated. Protracted 
temozolomide exposure may reduce MGMT activity. Brock and colleagues demonstrated 
safety of a low dose of temozolomide for up to 49 consecutive days, however the efficacy of 
this lower dose is unclear (Brock et al. 1998). Depletion of peripheral mononuclear MGMT 
has been demonstrated with more prolonged dosing regimens and unfortunately this has 
been associated with profound lymphocytopaenia and opportunistic infections (Tolcher et 
al. 2003; Wick et al. 2004; Wick&Weller 2005). More recent evidence suggest that daily 
dosing may be associated with improved outcome (Buttolo et al. 2006). Additionally, a 
dosing regimen of 14 days of treatment out of every 28 days has not only been shown to 
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lead to a progression free survival benefit, outcome with this treatment regimen was not 
significantly associated with MGMT promoter methylation (Wick et al. 2007).  
Treating patients with continuous 50mg/m2 at relapse after a standard temozolomide 
schedule of 150-200mg/m2 resulted in a PFS6 of 47-57% (Perry et al. 2008). The efficacy and 
safety of this continuous dose-intense temozolomide schedule for recurrent GBM was tested 
in a multicenter, phase II study, RESCUE. Overall, PFS6 in 116 patients with recurrent GBM 
was 24% (Perry et al. 2010). Not surprisingly, the best responding patients were those who 
were treated with conventional chemoradiotherapy. However, what was interesting was the 
similar benefit to treatment recorded in the patients who experienced early progression on 
standard therapy (Perry et al. 2010).  
2.3 IDH mutations 
The Cancer Genome Atlas (TCGA) efforts made the initial breakthrough discovery that 11% 
of glioblastomas harbour point mutations in cytoplasmic and mitochondrial NADP+-
dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) (Balss et al. 2008; Parsons et 
al. 2008; Dang et al. 2009). The normal function of the IDH enzymes is to convert isocitrate 
into ┙-ketoglutarate. Mutations, specifically at the arginine 132 (R132) codon, are more 
frequently observed in low grade and anaplastic gliomas and secondary glioblastomas (50-
93%) than mutations found in IDH2 [arginine 172 (R172) codon] (3-5%). No gliomas have 
been found to have point mutations in both IDH1 and IDH2 (Yan et al. 2009).  
 
A B
 
Fig. 4. Representative photomicrographs of IDH1 mutations detected with the Anti-Human 
IDH1 R132H Mouse Monoclonal Antibody (DIA-H09M) at x20 magnification (A) and x40 
(B) Photomicrographs were kindly donated by Dr Michael Buckland, Department of 
Neuropathology, University of Sydney. 
Hartmann and colleagues used an antibody which specifically detected the R132 mutation 
in IDH1 allowing assessment with simple immunohistochemistry (Hartmann et al. 2010). 
(Figure 4). The mutation was detected in 72% low grade astrocytomas (AII; n=227); 64% 
anaplastic astrocytomas (AA; n=228); 82% low grade oligodendroglioma (OII; n=128); 70% 
anaplastic oligodendroglioma (AO; n=174); 82% low grade oligoastrocytomas (OAII; n=76); 
66% anaplastic oligoastrocytoma (AOA; n=177) and 9% glioblastoma (GBM; n=521). What 
was most significant about this study was the progression free and overall survival curves. 
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In order of most favourable to poor survival: (1) AA with IDH1 mutation, (2) GBM with 
IDH1 mutation, (3) AA with IDH1 wild type and (4) GBM with IDH1 wild type. Routine 
testing for IDH1 mutations will have clinical ramifications regarding histological diagnosis 
and treatment schemes. The IDH1 mutation is of greater prognostic relevance than 
histopathological diagnosis according to the World Health Organisation (WHO) 
classification system (Hartmann et al. 2010). Subsidised treatment schemes approved for 
glioblastoma such as concomitant radiotherapy and temozolomide and bevacizumab (USA 
only) may need to be revised to allow anaplastic gliomas with IDH1 wild type status to be 
treated. 
Mutations of the codons in IDH1 and 2 lead to a loss in the production of ┙-ketoglutarate 
and a gain of the catalytic activity to produce 2-hydroxyglutarate (2-HG) (Xu et al. 2011). 2-
HG levels are highly elevated in IDH-mutated cancers and lead to genome wide histone and 
DNA methylation alterations (Xu et al., 2011; Dang et al., 2009). Hypermethylation at a large 
number of loci have been associated with IDH-mutated glioma suggesting that IDH 
mutation is associated with a distinct DNA methylation phenotype (Noushmehr et al. 2010; 
Christensen et al. 2011). GoldenGate array methylation data was obtained from 131 glioma 
patients (all types and histological grades) to interrogate methylation patterns associated 
with IDH mutation and survival. IDH1 mutations were present in 60% of tumours. Distinct 
differences between the numbers of significantly differentially hypermethylated loci were 
noted in IDH mutant tumours compared to IDH wild type tumours. Specific to IDH mutant 
tumours, cellular signalling pathways were hypermethylated whilst metabolism and 
biosynthesis pathways were hypermethylated (Christensen et al. 2011). This might be 
compensatory for the metabolic stress related to the mutation.  
In a series of elegant in vitro-based experiments, Yan’s group transformed human 
oligodendroglial (HOG) cells with IDH1-R132 or treated cells with 2-HG (Yan et al. 2009). 
They noted changes in gene expression common to both IDH1-R132 cells and 2-HG-treated 
cells when compared to IDH1-wildtype and untreated cells, implying that these changes 
were the result of increased 2HG (Reitman et al. 2010; Reitman&Yan 2010). However, 
reductions in glutamate and several glutamate-related metabolites were observed 
exclusively in the IDH1-R132 cells. Particular attention was paid to reduced levels of a 
common dipeptide in the brain, N-acetyl-aspartyl-glutamate (NAAG), however its 
contribution to pathogenesis remains unclear (Reitman et al. 2011).  
Recently, IDH mutations have been shown to be tightly associated with the presence of a 
glioma CpG island methylator phenotype (gCIMP) (Noushmehr et al. 2010). CIMPs are 
characterised by highly concordant DNA methylation of a subset of loci. Improved survival 
was observed in gliomas with IDH1 mutation and positive for gCIMP suggesting that there 
are molecular features within gCIMP gliomas that encourage a less aggressive phenotype. 
CIMP positive colon cancers also have a better prognosis. It is not known whether glioma 
cells acquire the mutation in IDH1 which then leads to genome histone and DNA 
methylation patterns, reflected by the presence of a gCIMP or that transcriptional silencing 
of gCIMP targets may provide the optimal environment for gliomas to acquire the mutation 
(genomic instability) (Noushmehr et al. 2010).  
Gliomas with IDH1 mutations as well as the presence of gCIMP displayed significantly 
better overall survival (median survival: 2.9 years) compared to all other patients (median 
survival: 1.04 years). The favourable survival observed in IDH1 mutation-gCIMP positive 
gliomas may be because these tumours are highly represented in the proneural subset of 
gliomas. Clinically, the prognostic utility of IDH1 mutations emerged in the NOA-04 trial. 
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IDH1 mutations conferred a significantly longer time to treatment failure (TTF) which was 
independent of histology, treatment, codeletion of 1p and 19q and MGMT promoter 
methylation status (Wick et al. 2009). IDH1 mutations as well as the gCIMP represent a 
significant breakthrough in how we diagnose patients. Testing for IDH1 mutations has 
quickly translated into routine diagnostic use. No doubt, IDH1 mutations and perhaps the 
gCIMP will be used to stratify patients for future clinical trials. Attention has shifted to 
examining therapeutic targets for IDH1 as well as the possibility of inducing mutations in 
IDH1 in GBMs that don’t possess the mutation.  
3. Use as predictive biomarkers 
Biomarkers which can foretell whether patients are resistant to a certain treatment and 
predict drug sensitivity are urgently needed. The success rate of matching biomarkers with 
treatments has been less than satisfactory. Fewer than 100 biomarkers have been validated 
for routine clinical practice, despite the publication of more than 150,000 claimed 
biomarkers. Impeding the successful translation of biomarkers into the clinical setting is 
non-standardised biological specimen and clinical data collection, particularly clinical 
information pertaining to drug sensitivity and progression free survival. In addition, far 
greater numbers of tumour specimens from patients treated uniformly may be needed to be 
analysed than what we previously assumed. 
The only biomarker with reported predictive value is MGMT promoter methylation. As 
discussed earlier in the MGMT section, the role of MGMT is to protect cells from alkylating 
damage specifically by removing the alkyl adducts from the O6 position of guanine and the 
O4 position of thymine and effectively restoring the DNA bases and prevent TMZ-induced 
cell death. However, the present NOA-04 trial does not support the suggestion that MGMT 
promoter methylation is simply predictive for response to alkylating chemotherapy (Wick et 
al. 2009). NOA-04 showed a striking difference in PFS between patients with versus without 
MGMT promoter methylation who were treated with radiotherapy alone. Thus MGMT 
promoter hypermethylation in anaplastic gliomas may be regarded as (1) a prognostic 
marker for good outcome in patients treated with radiotherapy or (2) predictive for response 
to radiotherapy itself.  
The most significant issue with implementing MGMT promoter methylation as a predictive 
test for TMZ therapy is that there is currently no alternative treatment strategy available for 
those patients with unmethylated MGMT tumours. Until alternative treatments are 
available and the MGMT test is more reliable and robust, will clinicians consider MGMT 
promoter methylation as a predictive test. 
4. Use of biomarkers in clinical trials 
Co-deletion of the chromosomal arms 1p and 19q is a requirement for entry of anaplastic 
gliomas into the CODEL study which is assessing the role of concomitant and adjuvant 
temozolomide added to standard radiotherapy and has temozolomide monotherapy in an 
observation arm. A phase III randomized sister study to CODEL, CATNON, examines 
radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-
1p/19q deleted anaplastic gliomas (Figure 5). This type of dual study design allows for the 
patient populations to be enriched in a specific marker, yet it doesn’t exclude either tumour 
types (codeleted and nondeleted 1p/19q). All specimens will also be tested for MGMT 
promoter methylation. 
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Fig. 5. Overview of the CATNON and CODEL trials 
A phase I/IIa trial examined the effectiveness of adding cilengitide to concurrent 
chemoradiotherapy (Stupp et al. 2010). This study demonstrated the effectiveness of 
cilengitide but also showed that there was a clear survival benefit in the patients with 
MGMT promoter methylation (Stupp et al. 2010). The phase III CENTRIC trial 
(recruitment closed in Feb, 2011) restricted recruitment to newly diagnosed GBM patients 
with confirmed MGMT methylation. An additional two phase II trials sponsored by the 
pharmaceutical company, EMD Serono, are designed to treat patients with unmethylated 
MGMT: CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients 
with Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status) and 
ExCentric. CORE (trial still open; May 2011) examines the efficacy of increasing the dose 
schedule of cilengitide (2000mg twice weekly and 2000mg five times per week) versus 
standard concurrent chemoradiotherapy (without cilengitide). The ExCentric trial 
(recruitment open, May 2011) has taken a much different approach. In this trial, 
procarbazine is added to the concurrent schedule of radiotherapy, TMZ, cilengitide and 
patients will be treated adjuvantly for an additional 6 cycles with the triple cocktail of 
cilengitide, TMZ and procarbazine. The patients have so far shown excellent toleration of 
this combination. 
The RTOG-0825 examines the effect of bevacizumab administered with radiotherapy 
compared to conventional concurrent chemoradiotherapy (TMZ) in primary GBM. All 
patients enrolled in this study will be tested for MGMT promoter methylation. Unique to 
this study, however, all samples will be prospectively tested with the nine-gene profile 
which separates the proneural GBM from the mesenchymal-angiogenic GBM (Colman et al. 
2010). It is becoming mandatory for future trial design to incorporate molecular inclusion 
criteria to identify the poorly responding patients from the patients who benefit.  
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5. Targeted therapies for glioblastoma 
Molecular targeted therapies specifically inhibit amplified or aberrant proteins that drive 
tumour cell growth. The key to targeted therapy is identifying a target whose inhibition will 
stop the growth of the tumour cell. Whilst this field has rapidly developed, our understanding 
at the molecular level of the precise role that potential targets have in tumorigenesis and the 
survival dependence that tumours have on these components has not progressed at the 
same rate. Unlike melanoma, lung and breast cancer, glioblastoma lacks significant driver 
mutations which are present in ample abundance and in all tumours. The TCGA analysis 
revealed a wide spectrum of molecular variation in glioblastoma. TCGA used global gene 
expression analysis to show aberrations occurred more commonly in genes whose protein 
products regulated the core cell growth signalling pathways that were already known to be 
important such as EGFR, PTEN, p53 and CDKN2A. One pathway which is frequently 
dysregulated is the receptor tyrosine kinase (RTK)/phosphatidylinositol 3-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) cascade. Approximately 86% of 
clinical samples analysed by the TCGA with both copy number and sequencing data had a 
genetic alteration in the RTK/PI3K pathway (Parsons et al. 2008). In addition, genetic 
alterations in two other core pathways; RB (87%) and TP53 (78%) were documented. At the 
time (3 years ago now) it was reasonable to suggest that all tumours be sequenced and the 
genetic aberrations be documented before selecting the targeted therapy. For example, for 
tumours with alterations in CDKN2A or CDKN2C or amplifications in CDK4 or CDK6, a 
CDK inhibitor should be recommended. Unfortunately, we underestimated the extent of 
genomic complexity and it is very doubtful that therapies targeted to a single genetic change 
will ever be effective. A range of molecular targeted drugs applied in combination or in 
addition to each other is needed (Jansen et al. 2010). In clinical practice, the multi-drug 
approach is currently limited by intellectual property. Most likely the efficacy of two drugs 
may require two competing pharmaceutical companies to work together.  
To understand why our current single targeted therapies are ineffective, it is useful to 
examine the earlier clinical studies with EGFR- and VEGF-targeted drugs. We can also glean 
value from trials using targeted therapy in other cancers. Even when the target of interest is 
much more prominent such as KRAS or BRAF, valuable lessons can still be learnt.  
5.1 Targeting the RTK/PI3K pathway  
In a study of 49 patients with recurrent glioblastoma, tumour shrinkage was evident in 9 
patients (25%) (Mellinghoff et al. 2005). Logically, it was of great interest to better 
understand the underlying molecular biology of these 9 responders. Pre-treatment tissue 
was only available for 7 of the responding patients and 19 patients who did not respond. 
The authors found coexpression of EGFRvIII and PTEN sensitised glioblastoma to erlotinib 
and correctly validated this finding in tissue samples from different institutions undergoing 
similar treatment (n=33) (Mellinghoff et al. 2005). Unfortunately, the relationship between 
EGFRvIII and intact PTEN co-expression did not translate to the subsequent prospective 
phase I/II trials (Brown et al. 2008; van den Bent et al. 2009). No relationship between 
aberrations in the RTK core and the EGFR inhibitor, lapatinib (Thiessen et al. 2010) or 
addition of erlotinib with the mTOR inhibitor, sirolimus (Reardon et al. 2010) were linked 
with response.  
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5.2 Targeting angiogenesis 
The development of anti-angiogenic agents for glioblastoma have been promising and 
include bevacizumab (Vascular endothelial growth factor [VEGF] antibody), cediranib 
(VEGF receptor antagonist), cilengitide (mentioned previously; integrin antagonist) and 
Enzastaurin (Protein Kinase-C-┚-antagonist).  
The preclinical and clinical data for cediranib treatment in glioblastoma looked very 
promising (Dietrich et al. 2009; Gerstner et al. 2011). Unfortunately, the International 
Multicentre Phase III trial, REGAL was negative. The REGAL study compared the use of 
cediranib alone, cediranib in combination with lomustine and lomustine plus placebo. In the 
325 patients with recurrent GBM studied, only 16% treated with cediranib monotherapy 
were alive and progression free at 6 months (APF6) compared to 34.5% in the combination 
group and 24.5% in the lomustine plus placebo group (results reported by T. Batchelor at the 
Society of Neuro-oncology Annual Meeting, 2010; (Ahluwalia 2011)). Akin to cediranib, 
preclinical and studies of enzastaurin showed good anti-glioma activity but failed to show 
any significant benefits when trialled in a phase III study comparing enzastaurin to 
lomustine. Although less toxicity was observed with enzastaurin, no significant differences 
in median progression free survival and overall survival were observed (Wick et al. 2011). 
The humanized antibody, Bevacizumab (Avastin), has received the most attention, with 
Food and Drug Administration (FDA) approval for use in recurrent GBM in the USA. No 
such approvals have been obtained in Europe and Australia. This is predominantly because 
there is only a modest overall survival benefit of 7.8-9.2 months suggesting a further 
improvement of efficacy is needed. Numerous phase II studies have shown modest survival 
benefits with bevacizumab either as a monotherapy or in combination with irinotecan 
(Chinot et al. 2011; Jakobsen et al. 2011; Lai et al. 2011; Prados et al. 2011; Reardon et al. 
2011). Consistent to all trials examining bevacizumab efficacy is the reduction of steroids for 
patients and valuable palliation with preservation of key performance status (KPS), 
supporting a role for bevacizumab as a therapy in late stage disease (Hofer et al. 2011). 
Whether bevacizumab results in true glioma cell destruction or is it merely its ability to 
control the perivascular leak, resulting in better symptom control (associated with 
improvement of gadolinium MRI) needs to be elucidated. 
An issue consistent with all trials of cediranib, enzastaurin and bevacizumab is their testing 
on recurrent glioblastoma as opposed to primary glioblastoma. Recurrent glioblastoma are 
already highly refractory to treatment and the potential benefits of these drugs may be 
missed. New studies are investigating bevacizumab up front with standard radiation 
therapy and temozolomide. This has shown to be well tolerated (Vredenburgh et al. 2011) 
and it is a strategy that the RTOG-0825 trial has incorporated (discussed previously).  
With all of these targeted therapies, it would seem obvious that the more target present, the 
more efficacious the drug. Unfortunately, this has not been the case. For example, why 
patients with high expression of VEGF have not shown strong response to bevacizumab? 
These issues pertaining to biomarkers in targeted therapy trials will be discussed in turn 
below:  
5.3 Many retrospective analyses of single arm investigations are performed in small 
and often heterogeneous cohorts of patients 
The co-expression of EGFRvIII and PTEN was first discovered in an initial test set consisting 
of 49 recurrent GBM treated with either gefitinib (n=37) or erlotinib (n=12). 26 patients with 
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clear-cut evidence of a response or tumour progression had sufficient tissue for molecular 
analysis. Hence, just over half of the originally small cohort was analysed for molecular 
biomarkers. The validation study used a different tissue type entirely as only paraffin-
embedded slides were available. Again, this material was untreated tumour tissue, not the 
recurrent lesion. The validation set was extremely underpowered (n=33) with only 8 
responders identified in this dataset. It is imperative that collaborations between different 
institutes and countries work together to increase the power of these biomarker studies.  
5.3.1 A lack of standardisation in the methods used for marker measurement 
Assays for biomarkers need to be reliable. The assay needs to give identical results if 
repeated in the same or in another laboratory. The result needs to be the same, even when 
different methodologies are used. And finally, we need to ask whether the test provides 
added value to clinical practice. This has often been a strong criticism of studies 
incorporating MGMT promoter methylation (as discussed previously) and unfortunately 
the same issues surround biomarkers for targeted therapies. The original study by 
Mellinghoff and colleagues used immunohistochemistry (IHC) to assess PTEN expression 
(Mellinghoff et al. 2005). The problem with this approach is the antibody used does not 
detect the full length PTEN protein. Should mutations arise in the C-terminal end of the 
protein, these would go undiscovered using IHC assay. IHC for EGFR is also contentious. 
EGFR overexpression in GBM is generally driven by EGFR amplification. The scoring of 
EGFR IHC can be variable and different antibodies have different specificities to the EGFR 
protein. Amplification of EGFR or more specifically gain of copy number is most commonly 
detected by fluorescence in situ hybridization (FISH) and can be routinely performed in 
most histopathological laboratories. What is puzzling is the lack of sequencing of both EGFR 
and PTEN genes in the subsequent phase I/II clinical trials assessing TKIs. The most 
frequent mutant form of EGFR is EGFR Variant III (EGFRvIII or EGFR delta) which is 
missing the ligand –binding domain resulting in the constitutive activation of the EGFR-
phosphoinositide 3-kinase pathway. IHC specific to the EGFRvIII mutant form is highly 
specific as too is the commonly used RT-PCR method. However, there are additional 
missense mutations encoding extracellular EGFR that have been shown to drive oncogenesis 
in vitro and can be inhibited by small-molecular tyrosine kinase inhibitors. 
The original pre-clinical/clinical study sequenced all exons and flanking intronic sequences 
for EGFR (kinase domain), the HER2/neu (kinase domain) and all exons of PTEN. FISH was 
also performed to detect EGFR amplification and RT-PCR was used to amplify EGFR (1044-
bp product) and EGFRvIII (243-bp product). In addition, EGFR and PTEN were examined 
with IHC (Mellinghoff et al. 2005). 26 of the 49 patients underwent sequencing, which 
included 6 patients who showed a response to erlotinib. No mutations were found. Van den 
Bent and colleagues assessed the benefits of erlotinib compared to temozolomide or 
cumustine in recurrent GBM in a randomized phase II study (van den Bent et al. 2009). 
Obtaining full data for all patients in this study was problematic. From 100 patients, PTEN 
expression could be determined in 82 patient cases and pAKT in 64 patients. Like the 
Mellinghoff study, no mutations in EGFR were detected, however only exons 19 to 21 were 
assessed. Although an association between EGFRvIII and EGFR amplification with poor 
overall survival was shown, no correlation between response and the co-expression of PTEN 
and EGFR was measured (van den Bent et al. 2009). In fact, no significant activity of 
erlotinib was observed. In another study of 65 patients, erlotinib efficacy was assessed in 
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combination with temozolomide (Prados et al. 2009). Again no association with EGFRvIII 
and PTEN and response was measured, however in this study, MGMT promoter 
methylation was associated with better response. EGFR was measured with FISH and IHC, 
PTEN and EGFRvIII were analysed by IHC. No mutational analysis of EGFR was 
undertaken. Reardon and colleagues assessed the combination of erlotinib with a mTOR 
inhibitor, sirolimus in recurrent GBM (Reardon et al. 2010). Again, EGFR, EGFRvIII, PTEN, 
PI3K and pS6 were assessed by IHC and no association for these markers with clinical 
response was found. Mutational analysis was not conducted. Moreover, the general 
methodologies did not differ in the studies addressing erlotinib and response and the Phase 
II studies could not validate the findings of Mellinghoff et al.  
Elegant biomarker studies have been associated with the anti-angiogenic drugs. Attention 
has focused predominantly on secreted factors and imaging modalities. Interleukin 6 (IL-6) 
is over-expressed in the majority of gliomas and functions as an immune regulator and an 
autocrine growth factor (Saidi et al. 2009). High starting levels of IL-6 may influence the 
efficacy of bevacizumab as it provides redundancy for the VEGF/VEGFR pathway and 
promotes an immune response that stimulates angiogenesis by non-VEGF mechanisms. 
Sorenson et al. reported the combination of MRI imaging (measured changes in vascular 
permeability/flow [Ktrans] and changes in microvessel volume) and circulating collagen IV 
levels in plasma to be predictive of outcome in glioblastoma patients treated with cediranib 
(Sorensen et al. 2009). The level of circulating endothelial progenitor cells (cEPCs) and viable 
circulating endothelial cells (cECs) has also been shown to correlate with response (Sorensen 
et al. 2009). The ability to identify changes in a tumour’s perfusion offers the potential to 
predict growth or regression. Dynamic susceptibility-weighted contrast-enhanced (DSC) 
MR imaging can be used to measure relative cerebral blood volume (rCBV) as a surrogate 
marker of perfusion. A pilot study of 16 patients with recurrent glioblastoma and treatment 
with bevacizumab found that MR perfusion imaging showed a significantly improved 
correlation with time to progression (Sawlani et al. 2011). Studies from Tsien (Tsien et al. 
2011) and Server (Server et al. 2011)- both show positive results for this scan in patients with 
PsPD. Only changes in the hypoxia inducing factor (HIF) 2 alpha [HIF2] have been shown 
to be promising surrogates of response to anti-angiogenic therapies (Mao et al. 2011). 
5.3.2 Methodologies chosen in the study may not represent a comprehensive analysis 
of multiple components of a specific pathway  
None of the studies examining erlotinib have comprehensively analysed the downstream 
components involved in EGFR signalling. Additional testing of PI3K and PS6 were added in 
some studies. It is very common for glioblastomas to have dysregulated signalling cascades 
downstream of EGFR, particular the negative feedback loops. Several growth factor 
pathways are also triggered. It’s not economically feasible in most instances to assess all 
aspects of the RTK/PI3K/AKT/mTOR signalling cascade. However, a new system of 
testing drugs and identifying which subtypes of glioblastoma are susceptible to the drug 
could be to use human glioblastoma xenograft panels serially passaged in nude mice. This 
model allows tumour burden to be monitored non-invasively and rapid assessment of 
biological pathways (Prasad et al. 2011).  
Feedback mechanisms also pose an issue with targeted therapies blocking angiogenesis. 
Tumours frequently recur after treatment with cediranib and bevacizumab and are 
refractory to further treatments. There have been different theories postulated as to why this 
“rebound” effect occurs. Tumours may switch to VEGF-independent angiogenic pathways 
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or vessel co-option. A commonly held theory is that recurrent glioblastomas switch their 
growth pattern after anti-VEGF treatment (di Tomaso et al. 2011). The tumour cells are 
exposed to an increased hypoxic environment leading to increased migration, invasion, 
heightened glycolysis and increased PI3K pathway activation. Combining bevacizumab 
with anti-glycolytic agents or PI3K inhibitors might be more effective. Tumour-initiating 
CD133+ve cells are radio-resistant and can self renew to reform tumours, suggesting that 
these cells are responsible for tumour relapse (Liu et al. 2009). More significantly, exposure 
to bevacizumab inhibited the maturation of tumour endothelial progenitors into the 
endothelium but not the differentiation of CD133+ cells into progenitor cells (Wang et al. 
2011). This fundamental study showed that there is a dynamic balance between the CD133+ 
cell population and tumour cells and we need to target the endothelial transition as well as 
VEGF.  
5.3.3 Not all mutations within a given gene are screened 
In simplistic terms, the plethora of TKIs are designed to be effective on patients harbouring 
EGFR mutations. However, in the majority of studies exploring gefitinib and erlotinib, the 
EGFR gene is not fully sequenced to identify variants and mutations. TCGA analyses have 
identified a high diversity of genes mutated within glioblastoma. As prices drop with Next 
Generation sequencing, capabilities to better define precise genetic aberrations associated 
with response to a specific treatment will improve. Copy number aberrations (amplifications 
and deletions) and structural aberrations (intra-chromosomal rearrangements- inversions, 
inverted/tandem duplications) are not detected using traditional Sanger sequencing in the 
lab. Our ability to assess these aberrations must improve at the rate that new targeted 
therapies are flooding the market. BRAF is a commonly deleted gene in approximately 8% 
of solid tumours, however over 30 different mutations in the BRAF gene have been 
implicated in cancer (Dienstmann&Tabernero 2011; Puzanov et al. 2011).  
5.3.4 A pathway-centric approach is needed 
As eluded to in our discussion of multiple pathways and feedback loops in any given target, 
we need to develop ways to target multiple points of a pathway akin to attacking the 
Achilles heel of the tumour. Recent data suggest that miRNA expression is tightly 
coordinated, and that each miRNA may target numerous messages. Thus, a specific miRNA 
has the potential to regulate several members of an entire signalling pathway. miRNAs 
negatively regulate their targets by one of two mechanisms: either by near perfect binding to 
the mRNA target and induction of miRNA-associated, multiprotein RNA-induced-silencing 
complex (miRISC), which results in accelerated mRNA decay (Yekta 2004; Wu 2006) or by 
less perfect binding to the target mRNA 3’-UTR and inhibition of translation through a RISC 
complex similar to, or identical with, the complex recruited in RNA interference (RNAi) 
(Humphreys et al. 2005; Pillai et al. 2005; Esquela-Kerscher&Slack 2006). 
miR-7 directly regulates the expression of EGFR in glioblastoma and has also been shown to 
directly attenuate the activation of AKT and ERK1/2 (extracellular signal-regulated kinase) 
indicating its ability to co-ordinately regulate EGFR signalling (Webster et al. 2009). We also 
showed that miR-124a attenuated glioblastoma migration and invasion at multiple points of 
the pathway (Fowler et al. 2011). New technologies are currently being developed to 
facilitate the use of miRNAs as a realistic therapeutic option. Until then, combination 
treatments and developing inhibitors which can affect a multiplicity of targets are critical. 
www.intechopen.com
 Glioma – Exploring Its Biology and Practical Relevance 
 
66
5.3.5 Differing response criterion 
The inability to accurately define endpoints from clinical trials makes the evaluation of new 
therapies subjective and significantly delays treatment development. At present overall 
survival (OS) and 6 month progression free survival (PFS6) are two defined end points 
accepted in most clinical trials testing for new GBM therapies. PFS6 relies on a combination 
of gadolinium enhanced MRI imaging and potentially subjective clinical evaluation. 
Seizures, depression and steroid induced myopathy can all influence clinical signs and 
symptoms. Since 1990, the MacDonald criterion has been used as an objective radiologic 
assessment of response in GBM. This two dimensional measurement has been mainstay for 
evaluating tumour response and is based upon measurements of the enhancing tumour area 
(the product of the maximal cross-sectional enhancing diameters) (Macdonald et al. 1990). 
With the advance of treatments administered to patients with GBM, the MacDonald Criteria 
has a number of important limitations. The MacDonald criteria does not discriminate 
measurable disease from non-measureable disease, cannot identify non-tumour related 
increases in enhancement and provides no use for the evaluation of anti-angiogenic drugs. 
Bevacizumab can cause accelerated regression of VEGF driven angiogenesis and rapid 
resolution of gadolinium MRI changes in responding patients. There is concern however as 
to whether anti-VEGF therapy results in true glioma cell destruction or their ability to 
control the perivascular leak, resulting in better symptom control (associated with 
improvement of gadolinium MRI). 
An international working group was formed to review and improve the response 
assessment criteria for high grade gliomas, coined Response Assessment in Neuro-Oncology 
(RANO) (Wen et al. 2010). The guidelines have devised a better standardisation of how 
clinicians measure response, which will ultimately result in a more uniform assessment of 
disease status across different centres. Unfortunately, the new RANO guidelines do not 
address the persistent problem of the irregularity of gliomas and the difficulty of measuring 
tumours treated with anti-angiogenic drugs, suggesting that volumetric measurements that 
count all enhancing and non-enhancing voxels may prove more accurate in the future.The 
RANO working party acknowledges that an important area of future research is the need to 
develop advanced novel MRI techniques.  
5.3.6 Inadequate tissue 
Biobanks or biorepositories play a critical role in the evolution of biomarkers, targets and 
targeted therapies. Five years ago, the NCI announced their plans to enlist dozens of bio-
repositories in the USA to provide large tumour numbers and use high-throughput DNA 
sequencing and computational biology to produce with new methods of detecting and 
treating cancers. Unfortunately sub-standard tissue and data collection provided a 
significant road block to the Cancer Genome Atlas effort. Biorepositories remain 
underfunded and unappreciated. Despite billions of dollars poured into cancer research, 
innovation in the field of biobanking is sadly lacking. Standard operating procedures (SOPs) 
are not consistent between sites, and sometimes differ within single institutes. 
Methodologies for preserving tissue vary and times between tumour removal and time of 
processing fluctuate. Significant genetic changes can occur between the time of tissue 
removal from the body and time of processing. The collection of tissue has to be taken 
seriously and investments need to be urgently made to promote basic, translational and 
clinical research as well as social gain in terms of improved cancer care and economic 
development. 
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Collection and storage of frozen tissue is critical for biomarker development. Many of our 
current biomarker assays are performed on Formalin Fixed Paraffin Embedded (FFPE) 
tissue. This type of tissue, whilst preserving morphology for diagnosis, induces problems 
for downstream molecular applications. High quality RNA is difficult to obtain from FFPE 
tissue and PCR amplification from FFPE DNA is limited to products of less than 200 base 
pairs. It is also difficult to control the processes leading up to tissue fixation. In a first class 
Neuro-oncology centre in Australia, FFPE blocks were being sent to Central Headquarters 
for MGMT methylation detection. Unfortunately, a sizeable batch of tissues were non-
determinative (could not be amplified). Tissue from surgeries performed on a Friday were 
fixed in formalin, however the laboratory was unattended over the weekend, resulting in 
the tissue submerged in formalin for up to 72 hours (routinely, formalin should be removed 
after 24 hours). 
Another issue that we are not taking into careful consideration are the molecular changes 
acquired in the tumour after treatment. Many biomarker studies are performed on tumour 
obtained at initial surgery event. This tissue has not been exposed to treatment. However, 
the majority of novel treatments are tested at the time of recurrence. Changes in 
chromosome aberrations and mismatch repair proteins have been detected in paired tumour 
specimens (primary and relapsed). Careful consideration of the tissue and its relevance to 
the clinical circumstance of the patient is required.  
6. Future directions for biomarker development 
To advance personalised medicine, a co-operative effort between cancer researchers and 
clinicians is urgently needed. There is very little collaboration between scientists working on 
targeted therapies such as the TKIs and anti-angiogenics...what worked, what didn’t? 
Specific consideration needs to be paid to increasing sample sizes, sequencing entire genes, 
implementing robust methodologies and taking a holistic approach to understanding 
pathways. Cancer is multifaceted and we urgently need to unravel these complexities. Two 
prospective biomarker trials have been encouraging: the I-SPY 2 (investigation of serial 
studies to predict your therapeutic response with imaging and molecular analysis 2) for 
women with locally advanced breast cancer (Barker et al. 2009) and BATTLE (Biomarker 
Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) for pre-treated 
patients with non-small cell lung cancer (NSLC) (Kim 2011). Both trials employ an adaptive 
phase II/III clinical trial design. The I-SPY 2 is performed as a neo-adjuvant trial. A core 
biopsy is provided and tested for Estrogen Receptor (ER), Progesterone Receptor (PR), 
Human Epidermal Growth Factor Receptor 2 (HER2) and MammaPrint status (a gene 
signature known to be predictive of outcome). Based upon the marker outcomes, the 
patients will be stratified into two arms of a standard neoadjuvant regime: paclitaxel (plus 
trastuzumab [Herceptin] for HER2+ patients followed by doxorubicin (Adriamycin) and 
cyclophosphamide (Cytoxan). Five new drugs will be trialled in the other arms (each being 
added to the standard therapy). Patients are currently being recruited. The BATTLE trial 
takes on a very similar adaptive design but differs in its examination of samples from post-
treated NSLC. Key drugs and associated biomarkers (Erlotinib/EGFR; Vandetanib/VEGFR; 
Erlotinib + bexarotene/ Retinoid + EGFR and Sorafenib/ KRAS/BRAF) were tested both as 
an equal randomisation design and an adaptive randomisation design. This trial confirmed 
that tumours harbouring mutations in KRAS/BRAF showed a disease control of 79% when 
treated with sorafenib but only 14% of the patients responded to erlotinib. Conversely, 
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sorafenib, although active against wild type or mutated KRAS, had worse disease control in 
patients with EGFR mutations. A limitation in applying these adaptive trial designs to 
glioblastoma will be adequate numbers. Additionally, the BATTLE trial identified that 
grouping mutations together were less predictive than individual markers. This may also 
impact on a highly heterogenous cancer such as glioblastoma. Nevertheless, these trials 
show that, with a highly integrated team of multidisciplinary investigators, better overall 
survival in glioblastoma is achievable. 
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